Azvudine, by Chinese drugmaker Genuine Biotech, outperformed Paxlovid in a study of 3600 hospitalised patients:
⬆️ survival rate
⬇️ reported side effects
Of note: #azvudine was particularly beneficial for patients initiating treatment >5 days after diagnosis.
www.news-medical.net/news/2025012...
⬆️ survival rate
⬇️ reported side effects
Of note: #azvudine was particularly beneficial for patients initiating treatment >5 days after diagnosis.
www.news-medical.net/news/2025012...
Azvudine beats paxlovid in reducing COVID-19 deaths
In hospitalized COVID-19 patients, azvudine shows lower all-cause mortality and fewer adverse events than Paxlovid, with added antitumor effects observed.
www.news-medical.net
January 22, 2025 at 1:32 AM
Azvudine, by Chinese drugmaker Genuine Biotech, outperformed Paxlovid in a study of 3600 hospitalised patients:
⬆️ survival rate
⬇️ reported side effects
Of note: #azvudine was particularly beneficial for patients initiating treatment >5 days after diagnosis.
www.news-medical.net/news/2025012...
⬆️ survival rate
⬇️ reported side effects
Of note: #azvudine was particularly beneficial for patients initiating treatment >5 days after diagnosis.
www.news-medical.net/news/2025012...
Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study
Study comparing the efficacy and safety of azvudine versus Paxlovid
#MedSky
www.nature.com/artic...
1/3
Study comparing the efficacy and safety of azvudine versus Paxlovid
#MedSky
www.nature.com/artic...
1/3
Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study
Signal Transduction and Targeted Therapy - Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a...
www.nature.com
January 17, 2025 at 12:36 PM
Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study
Study comparing the efficacy and safety of azvudine versus Paxlovid
#MedSky
www.nature.com/artic...
1/3
Study comparing the efficacy and safety of azvudine versus Paxlovid
#MedSky
www.nature.com/artic...
1/3
Henan, China 596 cancer patients with COVID-19 showed lower 31-day death and disease progression rates on azvudine than Paxlovid with no safety difference.
Azvudine may be a better antiviral option for this group.
www.nature.com/articles/s41...
Azvudine may be a better antiviral option for this group.
www.nature.com/articles/s41...
Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19 - Scientific Reports
Scientific Reports - Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19
www.nature.com
April 1, 2025 at 1:08 AM
Henan, China 596 cancer patients with COVID-19 showed lower 31-day death and disease progression rates on azvudine than Paxlovid with no safety difference.
Azvudine may be a better antiviral option for this group.
www.nature.com/articles/s41...
Azvudine may be a better antiviral option for this group.
www.nature.com/articles/s41...
Azvudine Significantly Cuts COVID-19 Death Risk in Kidney Patients
www.thailandmedical.news/news/azvudin...
www.thailandmedical.news/news/azvudin...
Azvudine Significantly Cuts COVID-19 Death Risk in Kidney Patients - Thailand Medical News
www.thailandmedical.news
April 10, 2025 at 3:58 AM
Azvudine Significantly Cuts COVID-19 Death Risk in Kidney Patients
www.thailandmedical.news/news/azvudin...
www.thailandmedical.news/news/azvudin...
China never have qualms referring to SARS-CoV as #AirborneAIDS or repurposing HIV ART medication such as #Azvudine to prevent and treat #LongCOVID
December 10, 2024 at 12:36 PM
China never have qualms referring to SARS-CoV as #AirborneAIDS or repurposing HIV ART medication such as #Azvudine to prevent and treat #LongCOVID
I'm not promoting Azvudine.
Azvudine is not available outside of Mainland China.
I'm informing you that your nation has done sweet duck all to attempt to address the ongoing #LongCOVID pandemic. #PublicHealth #WearN95
bsky.app/profile/ashe...
Azvudine is not available outside of Mainland China.
I'm informing you that your nation has done sweet duck all to attempt to address the ongoing #LongCOVID pandemic. #PublicHealth #WearN95
bsky.app/profile/ashe...
A study in Nature highlighted azvudine, a promising new treatment option for #Covid. A recent study of 40,876 hospitalized Covid patients found it reduced death risk by 18% compared to Paxlovid, with fewer adverse events. The drug inhibits viral RNA replication.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study - Signal Transduction a...
Signal Transduction and Targeted Therapy - Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a...
www.nature.com
March 25, 2025 at 11:48 AM
I'm not promoting Azvudine.
Azvudine is not available outside of Mainland China.
I'm informing you that your nation has done sweet duck all to attempt to address the ongoing #LongCOVID pandemic. #PublicHealth #WearN95
bsky.app/profile/ashe...
Azvudine is not available outside of Mainland China.
I'm informing you that your nation has done sweet duck all to attempt to address the ongoing #LongCOVID pandemic. #PublicHealth #WearN95
bsky.app/profile/ashe...
A study in Nature highlighted azvudine, a promising new treatment option for #Covid. A recent study of 40,876 hospitalized Covid patients found it reduced death risk by 18% compared to Paxlovid, with fewer adverse events. The drug inhibits viral RNA replication.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study - Signal Transduction a...
Signal Transduction and Targeted Therapy - Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a...
www.nature.com
February 6, 2025 at 2:35 AM
A study in Nature highlighted azvudine, a promising new treatment option for #Covid. A recent study of 40,876 hospitalized Covid patients found it reduced death risk by 18% compared to Paxlovid, with fewer adverse events. The drug inhibits viral RNA replication.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
#Medsky🧪 #IDSky #Immunosky #pharmasky #publichelth As more evidences #azvudine treatment in #COVID patients with #kidneydisease , #azvudine could reduced the risk of all mortality without significant adverse events
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com/doi/10.1002/...
April 10, 2025 at 4:32 AM
#Medsky🧪 #IDSky #Immunosky #pharmasky #publichelth As more evidences #azvudine treatment in #COVID patients with #kidneydisease , #azvudine could reduced the risk of all mortality without significant adverse events
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com/doi/10.1002/...
Henan Province, 4868 matched patients with COVID-19 and hypertension, found azvudine cut all cause mortality by 36% with no rise in serious adverse events, though anemia was more common.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Evaluating the effectiveness and safety of Azvudine for hospitalised patients with COVID-19 and hypertension: a multicenter retrospective cohort study - Scientific Reports
Scientific Reports - Evaluating the effectiveness and safety of Azvudine for hospitalised patients with COVID-19 and hypertension: a multicenter retrospective cohort study
www.nature.com
February 26, 2026 at 12:51 PM
Henan Province, 4868 matched patients with COVID-19 and hypertension, found azvudine cut all cause mortality by 36% with no rise in serious adverse events, though anemia was more common.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
In a study of 40,876 hospitalized COVID-19 patients across China, azvudine reduced all-cause mortality by 18% compared to Paxlovid.
Azvudine also showed fewer side effects and notable benefits for cancer patients, including potential antitumor effects.
www.nature.com/articles/s41...
Azvudine also showed fewer side effects and notable benefits for cancer patients, including potential antitumor effects.
www.nature.com/articles/s41...
Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study - Signal Transduction a...
Signal Transduction and Targeted Therapy - Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a...
www.nature.com
January 16, 2025 at 11:33 PM
In a study of 40,876 hospitalized COVID-19 patients across China, azvudine reduced all-cause mortality by 18% compared to Paxlovid.
Azvudine also showed fewer side effects and notable benefits for cancer patients, including potential antitumor effects.
www.nature.com/articles/s41...
Azvudine also showed fewer side effects and notable benefits for cancer patients, including potential antitumor effects.
www.nature.com/articles/s41...
Treatment for #LongCOVID:
Azvudine (FNC) is a nucleoside analog that inhibits viral replication through RdRp with thymus-homing and concentrations in PBMCs. While Azvudine is not a unique HIV treatment, the US, UK, and EU refuse to acknowledge that #LongCOVID is #AirborneAIDS. #WearN95
Azvudine (FNC) is a nucleoside analog that inhibits viral replication through RdRp with thymus-homing and concentrations in PBMCs. While Azvudine is not a unique HIV treatment, the US, UK, and EU refuse to acknowledge that #LongCOVID is #AirborneAIDS. #WearN95
March 25, 2025 at 11:43 AM
Treatment for #LongCOVID:
Azvudine (FNC) is a nucleoside analog that inhibits viral replication through RdRp with thymus-homing and concentrations in PBMCs. While Azvudine is not a unique HIV treatment, the US, UK, and EU refuse to acknowledge that #LongCOVID is #AirborneAIDS. #WearN95
Azvudine (FNC) is a nucleoside analog that inhibits viral replication through RdRp with thymus-homing and concentrations in PBMCs. While Azvudine is not a unique HIV treatment, the US, UK, and EU refuse to acknowledge that #LongCOVID is #AirborneAIDS. #WearN95
Guilin Medical University studied 400 hospitalized COVID-19 patients with diabetes and found Paxlovid like treatment nirmatrelvir ritonavir showed a lower trend in death and far less heart injury than azvudine though disease progression was similar.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
A real-world retrospective analysis comparing the effectiveness of Azvudine and Nirmatrelvir/Ritonavir in COVID-19 patients with diabetes - Scientific Reports
Azvudine and Nirmatrelvir/Ritonavir have been approved for the treatment of mild to moderate COVID-19 in adults at high risk for progression to severe disease. Diabetes is a high-risk complication of ...
www.nature.com
March 10, 2026 at 10:13 AM
Guilin Medical University studied 400 hospitalized COVID-19 patients with diabetes and found Paxlovid like treatment nirmatrelvir ritonavir showed a lower trend in death and far less heart injury than azvudine though disease progression was similar.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
GIVE LONG COVID PATIENTS ANTI VIRALS AND STOP JUST WATCHING THEM DIE THEN.
China did it two years ago when they repurposed HIV antivirals for Long Covid.
It's called Azvudine
Now ask yourself - WHY DO HIV MEDS WORK WITH LONG COVID?
so many similarities.
pmc.ncbi.nlm.nih.gov/articles/PMC...
China did it two years ago when they repurposed HIV antivirals for Long Covid.
It's called Azvudine
Now ask yourself - WHY DO HIV MEDS WORK WITH LONG COVID?
so many similarities.
pmc.ncbi.nlm.nih.gov/articles/PMC...
December 3, 2024 at 4:15 AM
GIVE LONG COVID PATIENTS ANTI VIRALS AND STOP JUST WATCHING THEM DIE THEN.
China did it two years ago when they repurposed HIV antivirals for Long Covid.
It's called Azvudine
Now ask yourself - WHY DO HIV MEDS WORK WITH LONG COVID?
so many similarities.
pmc.ncbi.nlm.nih.gov/articles/PMC...
China did it two years ago when they repurposed HIV antivirals for Long Covid.
It's called Azvudine
Now ask yourself - WHY DO HIV MEDS WORK WITH LONG COVID?
so many similarities.
pmc.ncbi.nlm.nih.gov/articles/PMC...
The effects of in vitro assays should be taken with caution. However, the tumour immune profiles assessing azvudine treatment give prospects for more work. "the antitumor mechanism and expanded use of azvudine require further validation through additional experiments and larger clinical trials"
3/3
3/3
January 17, 2025 at 12:36 PM
The effects of in vitro assays should be taken with caution. However, the tumour immune profiles assessing azvudine treatment give prospects for more work. "the antitumor mechanism and expanded use of azvudine require further validation through additional experiments and larger clinical trials"
3/3
3/3
A study in Henan, China, analyzed 657 COVID-19 patients with kidney disease and found that Azvudine and Paxlovid had similar effectiveness in preventing death and disease progression.
However, Azvudine showed fewer side effects.
bmcinfectdis.biomedcentral.com/articles/10....
However, Azvudine showed fewer side effects.
bmcinfectdis.biomedcentral.com/articles/10....
Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study - BMC Infectious Diseases
Background Patients with kidney disease (KD) are at high risk of contracting COVID-19 and developing severe disease. There is still a lack of guidance regarding the treatment of COVID-19 in patients w...
bmcinfectdis.biomedcentral.com
February 26, 2025 at 3:08 PM
A study in Henan, China, analyzed 657 COVID-19 patients with kidney disease and found that Azvudine and Paxlovid had similar effectiveness in preventing death and disease progression.
However, Azvudine showed fewer side effects.
bmcinfectdis.biomedcentral.com/articles/10....
However, Azvudine showed fewer side effects.
bmcinfectdis.biomedcentral.com/articles/10....
Efficacy Of Azvudine To Treat COVID-19 Questioned! - Thailand Medical News
www.thailandmedical.news
June 21, 2024 at 5:23 AM
Fewer adverse events were observed in the azvudine group.
Potential late benefit of azvudine (95% CI: 0.676–0.987), was there was no obviously difference in composite disease progression.
The most notable effect was in patients with malignant tumours.
2/3
Potential late benefit of azvudine (95% CI: 0.676–0.987), was there was no obviously difference in composite disease progression.
The most notable effect was in patients with malignant tumours.
2/3
January 17, 2025 at 12:36 PM
Fewer adverse events were observed in the azvudine group.
Potential late benefit of azvudine (95% CI: 0.676–0.987), was there was no obviously difference in composite disease progression.
The most notable effect was in patients with malignant tumours.
2/3
Potential late benefit of azvudine (95% CI: 0.676–0.987), was there was no obviously difference in composite disease progression.
The most notable effect was in patients with malignant tumours.
2/3
Looks like Azvudine is the new Paxlovid...
www.news-medical.net/news/2025012...
www.news-medical.net/news/2025012...
January 23, 2025 at 7:03 AM
Looks like Azvudine is the new Paxlovid...
www.news-medical.net/news/2025012...
www.news-medical.net/news/2025012...
link.springer.com/article/10.1...
#Oncosky
This 1st analysis the efficacy & safety of #azvudine vs #Paxlovid in cancer patients with #COVID , azvudine significantly reduced the risk of all-cause mortality & composite disease progression among cancer patients with COVID vs with Paxlovid.
#Oncosky
This 1st analysis the efficacy & safety of #azvudine vs #Paxlovid in cancer patients with #COVID , azvudine significantly reduced the risk of all-cause mortality & composite disease progression among cancer patients with COVID vs with Paxlovid.
Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study - BMC Infectious Diseases
Background Patients with kidney disease (KD) are at high risk of contracting COVID-19 and developing severe disease. There is still a lack of guidance regarding the treatment of COVID-19 in patients w...
link.springer.com
April 10, 2025 at 4:39 AM
link.springer.com/article/10.1...
#Oncosky
This 1st analysis the efficacy & safety of #azvudine vs #Paxlovid in cancer patients with #COVID , azvudine significantly reduced the risk of all-cause mortality & composite disease progression among cancer patients with COVID vs with Paxlovid.
#Oncosky
This 1st analysis the efficacy & safety of #azvudine vs #Paxlovid in cancer patients with #COVID , azvudine significantly reduced the risk of all-cause mortality & composite disease progression among cancer patients with COVID vs with Paxlovid.